Fate Therapeutics Inc


Prices are adjusted according to historical splits.

Fate Therapeutics Inc Stock Price


Today's Low:
Today's High:
Open Price:
52W Low:
52W High:
Prev. Close:

Company Statistics

Market Cap.:
$546.76 million
Book Value:
Revenue TTM:
$96.30 million
Operating Margin TTM:
Gross Profit TTM:
Profit Margin:
Return on Assets TTM:
Return on Equity TTM:

Company Profile

Fate Therapeutics Inc had its IPO on 2013-10-01 under the ticker symbol FATE.

The company operates in the Healthcare sector and Biotechnology industry. Fate Therapeutics Inc has a staff strength of 551 employees.

Stock update

Shares of Fate Therapeutics Inc opened at $5.57 at the start of the last trading session i.e. 2023-03-19.

The stocks traded within a range of $5.39 - $5.57, and closed at $5.54.

This is a -0.54% slip from the previous day's closing price.

A total volume of 17,427,100 shares were traded at the close of the day’s session.

In the last one week, shares of Fate Therapeutics Inc have increased by +3.55%.

Fate Therapeutics Inc's Key Ratios

Fate Therapeutics Inc has a market cap of $546.76 million, indicating a price to book ratio of 2.8832 and a price to sales ratio of 20.0077.

In the last 12-months Fate Therapeutics Inc’s revenue was $96.30 million with a gross profit of $-224154000 and an EBITDA of $-294628000. The EBITDA ratio measures Fate Therapeutics Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Fate Therapeutics Inc’s operating margin was -320.24% while its return on assets stood at -23.69% with a return of equity of -48.46%.

In Q4, Fate Therapeutics Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 159.9%.

Fate Therapeutics Inc’s PE and PEG Ratio

Forward PE
Trailing PE

Its diluted EPS in the last 12-months stands at $-2.94 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Fate Therapeutics Inc’s profitability.

Fate Therapeutics Inc stock is trading at a EV to sales ratio of 15.9288 and a EV to EBITDA ratio of -3.6966. Its price to sales ratio in the trailing 12-months stood at 20.0077.

Fate Therapeutics Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$705.56 million
Total Liabilities
$114.05 million
Operating Cash Flow
Capital Expenditure
$6.68 million
Dividend Payout Ratio

Fate Therapeutics Inc ended 2023 with $705.56 million in total assets and $0 in total liabilities. Its intangible assets were valued at $705.56 million while shareholder equity stood at $483.94 million.

Fate Therapeutics Inc ended 2023 with $0 in deferred long-term liabilities, $114.05 million in other current liabilities, 97000.00 in common stock, $-1050804000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $61.33 million and cash and short-term investments were $436.23 million. The company’s total short-term debt was $5,628,000 while long-term debt stood at $0.

Fate Therapeutics Inc’s total current assets stands at $502.07 million while long-term investments were $4.94 million and short-term investments were $374.89 million. Its net receivables were $38.48 million compared to accounts payable of $8.27 million and inventory worth $0.

In 2023, Fate Therapeutics Inc's operating cash flow was $0 while its capital expenditure stood at $6.68 million.

Comparatively, Fate Therapeutics Inc paid $0 in dividends in 2023.

Other key metrics

Current Trading Price
52-Week High
52-Week Low
Analyst Target Price

Fate Therapeutics Inc stock is currently trading at $5.54 per share. It touched a 52-week high of $43.12 and a 52-week low of $43.12. Analysts tracking the stock have a 12-month average target price of $8.27.

Its 50-day moving average was $5.98 and 200-day moving average was $19.16 The short ratio stood at 7.37 indicating a short percent outstanding of 0%.

Around 152.4% of the company’s stock are held by insiders while 11212% are held by institutions.

Frequently Asked Questions About Fate Therapeutics Inc

The stock symbol (also called stock or share ticker) of Fate Therapeutics Inc is FATE

The IPO of Fate Therapeutics Inc took place on 2013-10-01

Similar Industry Stocks (Biotechnology)

Last Price
Tecogen Inc (TGEN)

Most Active

Last Price

Top Gainers

Last Price

Top Losers

Last Price


Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma and FT522, to treat lymphoma and autoimmune disorders; and CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.


12278 Scripps Summit Drive, San Diego, CA, United States, 92131